BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36573296)

  • 1. Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.
    Parisi R; Patel RR; Rood G; Bowden A; Turco G; Korones DN; Andolina JR; Comito M; Barth M; Weintraub L
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30139. PubMed ID: 36573296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
    Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
    Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
    Patel RR; Ramkissoon SH; Ross J; Weintraub L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
    Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
    Hotz MJ; O'Halloran EA; Hill MV; Hayden K; Zaladonis AG; Deng M; Olszanski AJ; Reddy SS; Wu H; Luo B; Farma JM
    Melanoma Res; 2022 Apr; 32(2):112-119. PubMed ID: 35213415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
    Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
    J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Time to Diagnosis on Morbidity and Survival in Children With Malignant Central Nervous System Tumors.
    Ronsley R; Crowell C; Irvine M; Kang M; Goldman RD; Erker C; Cheng S
    J Pediatr Hematol Oncol; 2023 Mar; 45(2):e188-e193. PubMed ID: 35129148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
    Liu KX; Shang HH; Cacciotti C; Everdell E; Aizer AA; Rahman R; Malinowski S; Meredith DM; Kamihara J; Wen PY; Ligon KL; Chi SN; Marcus KJ; Yeo KK; Alexandrescu S; Haas-Kogan DA
    J Neurooncol; 2022 May; 157(3):499-510. PubMed ID: 35384518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
    Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
    Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
    Tian Y; Rich BE; Vena N; Craig JM; Macconaill LE; Rajaram V; Goldman S; Taha H; Mahmoud M; Ozek M; Sav A; Longtine JA; Lindeman NI; Garraway LA; Ligon AH; Stiles CD; Santagata S; Chan JA; Kieran MW; Ligon KL
    J Mol Diagn; 2011 Nov; 13(6):669-77. PubMed ID: 21884820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection.
    Dal Bo M; Polano M; Ius T; Di Cintio F; Mondello A; Manini I; Pegolo E; Cesselli D; Di Loreto C; Skrap M; Toffoli G
    J Transl Med; 2023 Jul; 21(1):450. PubMed ID: 37420248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
    Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
    J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
    Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
    Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
    Robert C; Lewis KD; Gutzmer R; Stroyakovskiy D; Gogas H; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Caro I; Forbes H; Shah K; Yan Y; Li H; McArthur GA; Ascierto PA
    Ann Oncol; 2022 May; 33(5):544-555. PubMed ID: 35131452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.